Repligen Co. (NASDAQ:RGEN) Stock Position Lifted by Alliancebernstein L.P.

Alliancebernstein L.P. grew its position in Repligen Co. (NASDAQ:RGEN) by 23.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,010,896 shares of the biotechnology company’s stock after acquiring an additional 191,439 shares during the quarter. Alliancebernstein L.P. owned approximately 1.80% of Repligen worth $145,508,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Premier Fund Managers Ltd bought a new stake in Repligen during the fourth quarter valued at $592,000. Pictet Asset Management Holding SA boosted its holdings in shares of Repligen by 14.4% in the 4th quarter. Pictet Asset Management Holding SA now owns 7,879 shares of the biotechnology company’s stock valued at $1,134,000 after buying an additional 992 shares during the period. Norges Bank bought a new stake in shares of Repligen during the 4th quarter valued at about $24,034,000. Sava Infond d.o.o. acquired a new stake in Repligen during the fourth quarter worth about $29,000. Finally, Pier Capital LLC lifted its holdings in Repligen by 1.2% in the fourth quarter. Pier Capital LLC now owns 65,109 shares of the biotechnology company’s stock worth $9,372,000 after acquiring an additional 766 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Repligen

In related news, Director Margaret Pax acquired 250 shares of Repligen stock in a transaction dated Monday, March 17th. The stock was acquired at an average cost of $150.69 per share, with a total value of $37,672.50. Following the purchase, the director now directly owns 1,043 shares in the company, valued at $157,169.67. The trade was a 31.53 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 1.20% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently commented on RGEN shares. Royal Bank of Canada upped their target price on Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a report on Friday, February 21st. JPMorgan Chase & Co. increased their target price on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research report on Friday, February 21st. Canaccord Genuity Group raised their target price on Repligen from $165.00 to $170.00 and gave the company a “hold” rating in a research note on Friday, February 21st. TD Cowen assumed coverage on shares of Repligen in a research report on Monday, February 10th. They set a “buy” rating and a $200.00 price target for the company. Finally, Evercore ISI started coverage on shares of Repligen in a research report on Tuesday, March 18th. They issued an “in-line” rating and a $155.00 price objective on the stock. One analyst has rated the stock with a sell rating, six have given a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, Repligen currently has an average rating of “Hold” and a consensus target price of $178.64.

Repligen Stock Performance

Shares of NASDAQ RGEN opened at $128.50 on Wednesday. Repligen Co. has a 1 year low of $113.50 and a 1 year high of $182.52. The firm has a market cap of $7.22 billion, a P/E ratio of -251.96, a PEG ratio of 4.54 and a beta of 0.95. The stock has a fifty day moving average price of $152.75 and a two-hundred day moving average price of $148.00. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44.

Repligen (NASDAQ:RGEN) last announced its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The business had revenue of $167.55 million during the quarter, compared to analysts’ expectations of $167.58 million. Research analysts forecast that Repligen Co. will post 1.72 EPS for the current fiscal year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.